377 results on '"Pawlitzki, Marc"'
Search Results
2. Flow cytometry identifies changes in peripheral and intrathecal lymphocyte patterns in CNS autoimmune disorders and primary CNS malignancies
3. Neuropsychiatric symptoms and lifelong mental activities in cerebral amyloid angiopathy – a cross-sectional study
4. The three-year evolution of Germany’s Digital Therapeutics reimbursement program and its path forward
5. Ravulizumab in myasthenic crisis: the first case report
6. Digitale Medizin in der neurologischen Forschung – zwischen Hype und Evidenz
7. Inter-alpha-trypsin inhibitor heavy chain H3 is a potential biomarker for disease activity in myasthenia gravis
8. Senescent fibro-adipogenic progenitors are potential drivers of pathology in inclusion body myositis
9. Identification of disease phenotypes in acetylcholine receptor-antibody myasthenia gravis using proteomics-based consensus clustering
10. Introducing electronic monitoring of disease activity in patients with chronic inflammatory demyelinating polyneuropathy (EMDA CIDP): trial protocol of a proof of concept study
11. Supporting the differential diagnosis of connective tissue diseases with neurological involvement by blood and cerebrospinal fluid flow cytometry
12. Repurposing drugs against Alzheimer’s disease: can the anti-multiple sclerosis drug fingolimod (FTY720) effectively tackle inflammation processes in AD?
13. Classification of neurological diseases using multi-dimensional cerebrospinal fluid analysis
14. K2P2.1 is a regulator of inflammatory cell responses in idiopathic inflammatory myopathies
15. Treatment of autoimmunity: The impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders
16. The PNS Nurse Program
17. Skeletal muscle provides the immunological micro-milieu for specific plasma cells in anti-synthetase syndrome-associated myositis
18. Cellular senescence in neuroinflammatory disease: new therapies for old cells?
19. Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses
20. Real-world evidence on siponimod treatment in patients with secondary progressive multiple sclerosis
21. Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients
22. Myositis in Germany: epidemiological insights over 15 years from 2005 to 2019
23. K2P18.1 translates T cell receptor signals into thymic regulatory T cell development
24. Risk factors for intracerebral hemorrhage in small-vessel disease and non-small-vessel disease etiologies—an observational proof-of-concept study
25. Neutrophil granulocytes promote flow stagnation due to dynamic capillary stalls following experimental stroke
26. The Innate Immune Response Characterizes Posterior Reversible Encephalopathy Syndrome
27. Failed, Interrupted, or Inconclusive Trials on Neuroprotective and Neuroregenerative Treatment Strategies in Multiple Sclerosis: Update 2015–2020
28. Association of Clinical Relapses With Disease Outcomes in Multiple Sclerosis Patients Older Than 50 Years.
29. Clinical and Diagnostic Features of Post-Acute COVID-19 Vaccination Syndrome (PACVS).
30. SARS-CoV-2 Vaccination and Neuroimmunological Disease
31. The Use of Nitrosative Stress Molecules as Potential Diagnostic Biomarkers in Multiple Sclerosis
32. Intravenous methadone causes acute toxic and delayed inflammatory encephalopathy with persistent neurocognitive impairments
33. Failed, Interrupted, or Inconclusive Trials on Immunomodulatory Treatment Strategies in Multiple Sclerosis: Update 2015–2020
34. Risiken und Chancen von Immuntherapien in Zeiten der Coronavirus-2019-Pandemie
35. Therapeutic Strategies to Potentially Cure Multiple Sclerosis: Insights into the Mechanisms of Autologous Hematopoietic Stem Cell Transplantation
36. Evaluation of Age-Dependent Immune Signatures in Patients With Multiple Sclerosis
37. Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19
38. Chronic Fatigue and Dysautonomia following COVID-19 Vaccination Is Distinguished from Normal Vaccination Response by Altered Blood Markers
39. Chronic Fatigue and Dis-Autonomy following COVID-19 Vaccination is Distinguished from Normal Vaccination Response by Altered Blood Markers
40. A study of the geographic accessibility of outpatient memory clinics in Germany
41. Ofatumumab-induced severe reactivation of psoriasis in a patient with multiple sclerosis.
42. Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation
43. “Neurological manifestations of COVID-19” - guideline of the German society of neurology
44. Classifying flow cytometry data using Bayesian analysis helps to distinguish ALS patients from healthy controls
45. CD8+ T cell-mediated endotheliopathy is a targetable mechanism of neuro-inflammation in Susac syndrome
46. Immune Checkpoint Inhibition–Related MyastheniaMyositis-Myocarditis Responsive to Complement Blockade.
47. Guideline for the management of myasthenic syndromes.
48. MS optic neuritis-induced long-term structural changes within the visual pathway
49. Eculizumab treatment alters the proteometabolome beyond the inhibiton of complement
50. Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.